We note with interest that Ernens et al. found that heart rate was depressed, in contrast to the relative tachycardia that is usually present in anemia-associated human heart failure. 1 These findings raise a thought-provoking conundrum regarding the cause of bradycardia and its impact on cardiac function in this zebrafish model.
One possibility is that bradycardia represents a primary response to heart failure.
Since cardiac output = heart rate × stroke volume, an adaptive increase in heart rate serves as an important physiological response to maintain cardiac output in settings of contractile dysfunction. A true bradycardia would therefore accelerate a decline in overall cardiac performance in low cardiac output states where myocardial contractile function is already compromised. The possibility that zebrafish are incapable of developing a compensatory increase in heart rate seems unlikely, however, given that tachycardia has been documented in a heart failure model associated with a sarcomere protein mutation. 3 Moreover, in our hands, we have noted a dose-dependent tachycardia during epinephrine administration in wild-type TE fish aged 6 months (Fig. 1A, 1B ), demonstrating that zebrafish are able to mount an appropriate chronotropic response to increased sympathetic stimulation.
Another possibility is that bradycardia might be indicative of advanced disease and a decompensated state. Phenylhydrazine (2.5 µg/mL) results in profound hemolytic anemia (relative hemoglobin <10% that of untreated animals). may have contributed to their heart rate results. 2 These factors would apply equally to wildtype and anemic fish, however, and thus do not explain the observed differences between groups. 2 A parsimonious explanation is that anemic zebrafish have a substantially greater susceptibility than healthy zebrafish to cardiodepressant effects of anesthesia. We also found that a similar dose of tricaine caused bradycardia in anemic zebrafish, with progressive reductions of heart rate occurring with increasing duration of anesthetic exposure (Fig. 1C,   1D ).
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